PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature

Creative Commons License

Muselaers S., ERDEM S., Bertolo R., Ingels A., KARA Ö., Pavan N., ...More

JOURNAL OF CLINICAL MEDICINE, vol.11, no.7, 2022 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 11 Issue: 7
  • Publication Date: 2022
  • Doi Number: 10.3390/jcm11071829
  • Journal Name: JOURNAL OF CLINICAL MEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, Directory of Open Access Journals
  • Keywords: PSMA PET, CT, renal cell carcinoma, kidney cancer, imaging, MEMBRANE ANTIGEN, F-18-DCFPYL PET/CT, F-18-FDG PET/CT, TOMOGRAPHY, EXPRESSION, NEOVASCULATURE, RECURRENCE, TRACER, TUMORS
  • Open Archive Collection: AVESIS Open Access Collection
  • Istanbul University Affiliated: Yes

Abstract

Although the vast majority of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging occurs in the field of prostate cancer, PSMA is also highly expressed on the cell surface of the microvasculature of several other solid tumors, including renal cell carcinoma (RCC). This makes it a potentially interesting imaging target for the staging and monitoring of RCC. The objective of this review is to provide an overview of the current evidence regarding the use of PSMA PET/Computed Tomography in RCC patients.